bioRxivNeurosciencePreprint
Cortical thickness changes precede high levels of amyloid by at least seven years
James M. RoeiD, William Jagust, Susan M. LandauiD, Theresa M. HarrisoniD, Håkon GrydelandiD, Maksim SlivkaiD, José Luis Alatorre WarreniD, Pablo F. GarridoiD, Øystein SørenseniD, Edvard GrødemiD, Tyler J. WardiD, Esten Høyland LeonardseniD, Tormod FladbyiD, Atle BjørnerudiD, Kristine Beate WalhovdiD, Anders M. FjelliD, Dídac Vidal-piñeiro AiD, Yunpeng WangiD
Abstract
Alzheimers disease (AD) is now defined based on its underlying brain pathology1, with the presence of amyloid (A{beta}) plaques at high enough levels sufficient to warrant a diagnosis in the absence of cognitive symptoms. High levels of PET-detectable A{beta} are widely thought to be the first imaging marker, with structural brain changes detectable on MRI scans thought to occur later. We combined 4570 longitudinal MRIs and 1684 A{beta} PET scans from three cognitively healthy cohorts to test the difference in cortical thickness and its change between those that subsequently converted to be A{beta}-positive or stayed A{beta}-negative, using MRIs acquired exclusively in the years before conversion. We found those that subsequently developed elevated A{beta} levels show both thicker cortex and less cortical thinning, even when the last MRI used to estimate their thickness trajectories was acquired at least seven years before conversion. Many effects remained when accounting for quantitative A{beta} levels, suggesting some cortical thickness effects may be partly independent of A{beta}. Differences in cortical thickness and its change between converters and A{beta}-negative individuals showed moderate alignment with patterns of A{beta} deposition, and the timing of thickness changes tracked the temporal progression of A{beta} accumulation. Thus, if amyloid is AD1, we show that high levels of PET-detectable amyloid are not the first imaging marker of AD, as cortical thickness changes can be traced years before pathological amyloid. This has implications for understanding the sequence of events leading up to the earliest stages of AD.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Amyloid-beta, p-tau, and reactive microglia load are correlates of MRI cortical atrophy in Alzheimer's disease
Irene Frigerio, Baayla D.C. Boon, … Laura E. Jonkman·bioRxiv·Jun 16, 2021
- Spatial relationships between white matter degeneration, amyloid load and cortical volume in amnestic mild cognitive impairment
Ileana Jelescu, Timothy M. Shepherd, … Els Fieremans·bioRxiv·Oct 13, 2018
- Theta band-power shapes amyloid-driven longitudinal EEG changes in pre-clinical Alzheimer's Disease
Giuseppe Spinelli, Hovagim Bakardjian, … Nathalie George·bioRxiv·Feb 4, 2022
- Time between milestone events in the Alzheimer's disease amyloid cascade
Philip S. Insel, Michael Donohue, … Niklas Mattsson·NeuroImagePeer-reviewed·Dec 24, 2020
- Cortical thinning in temporal pole, a core region in Alzheimer's disease, in non-demented, middle-aged APOE-e4 and PICALM-AA/AG carriers
Patrycja Dzianok, Jakub Wojciechowski, … Ewa Kublik·Neurobiology of AgingPeer-reviewed·Jul 21, 2026
- Basal forebrain volume is associated with cortical amyloid burden in cognitively unimpaired older adults at varying genetic risk for Alzheimers disease
Gawon Cho, Kaitlin Kelly, … Ryan S. O’Dell·The American Journal of Geriatric Psychiatry Open Science Education and PracticePeer-reviewed·May 14, 2026